This firm currently holds 24.56
M in liabilities with Debt to Equity (D/E) ratio of 0.52, which is about average as compared to similar companies. The company has a current ratio of 2.68, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Applied Genetic until it has trouble settling it off, either with new capital or with free cash flow. So, Applied Genetic's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Applied Genetic Tech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Applied to invest in growth at high rates of return. When we think about Applied Genetic's use of debt, we should always consider it together with cash and equity.
We provide trade advice to complement the prevailing
expert consensus on Applied Genetic Tech. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
We determine the current worth of Applied Genetic using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Applied Genetic based exclusively on its
fundamental and basic
technical indicators. By analyzing Applied Genetic's
financials, quarterly and monthly indicators, and related drivers such as
dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of
Applied Genetic's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Applied Genetic. We calculate exposure to Applied Genetic's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to Applied Genetic's related companies.
Watch out for price decline
Please consider monitoring Applied Genetic on a daily basis if you are holding a position in it. Applied Genetic is trading at a penny-stock level, and the possibility of delisting is much higher compared to other delisted stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Applied Genetic stock to be traded above the $1 level to remain listed. If Applied Genetic stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
Applied Genetic Investment Alerts
Applied investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Applied Genetic performance across your portfolios.Please check all
investment alerts for Applied
Applied Genetic Valuation Ratios as Compared to Competition
Our valuation model uses many indicators to compare Applied value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Applied Genetic competition to find
correlations between indicators driving the intrinsic value of Applied.
Detailed Perspective On Applied Genetic
The big decline in price over the last few months for Applied Genetic Tech could raise concerns from investors as the firm is trading at a share price of
0.39 on
505,207 in volume. The company executives failed to add value to investors and position the firm supply of money to exploit
market volatility in
August. However, diversifying your holdings with Applied Genetic Tech or similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 8.79. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Applied Genetic partners.
| 2020 | 2021 | 2022 (projected) |
Interest Expense | 1.51 M | 1.73 M | 1.87 M | Gross Profit | 500 K | 575 K | 590.13 K |
Margins Breakdown
Applied profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Applied Genetic itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Applied Genetic profit margins.
| Operating Margin | (12.95) |
| EBITDA Margin | (16.63) |
| Gross Margin | 0.89 |
| Profit Margin | (17.28) |
Applied Genetic Average Assets is increasing over the last 8 years. Also, Applied Genetic Net Income Per Employee is somewhat stable at the moment.
Our perspective of the current Applied Genetic rise
Current treynor ratio is at -1.35.
As of the 21st of September, Applied Genetic shows the
mean deviation of 4.22, and Risk Adjusted Performance of
(0.09). Applied Genetic Tech
technical analysis gives you the methodology to make use of
historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of
historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen
technical drivers for Applied Genetic Tech, which can be compared to its rivals. Please confirm
Applied Genetic Tech information ratio and the
relationship between the maximum drawdown and
skewness to decide if Applied Genetic Tech is priced correctly, providing market reflects its regular price of 0.39 per share. As
Applied Genetic Tech appears to be a penny stock we also recommend to validate its
total risk alpha numbers.
Our Conclusion on Applied Genetic
Whereas some other companies under the biotechnology industry are still a bit expensive, Applied Genetic may offer a potential longer-term growth to investors. To conclude, as of the 21st of September 2022, our analysis shows that Applied Genetic follows the market closely. The company is
undervalued and projects
average chance of distress for the next 2 years. Our present 90 days buy-sell recommendation on the company is
Cautious Hold.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Ellen Johnson is a Member of Macroaxis Editorial Board. Ellen covers public companies in North America, focusing primarily on valuation and volatility. Six years of experience in predictive investment analytics and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Applied Genetic. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
